Active Filters
- 2022Clear filter
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-12/FrontLineHead.Blanke.2022-web-sized_2.png?itok=QlXpgHfG)
Dec 23, 2022
![journal article title page](/sites/default/files/styles/news_recent/public/news/2022-12/NCTN-impact-cost-graphic-4.jpg?itok=jB3LfJuN)
Dec 19, 2022
Four decades of NCI-funded NCTN trials gave U.S. patients 14.2 million life-years for a federal investment of $326 per life-year gained
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-12/FrontLineHead.Blanke.2022-web-sized_1.png?itok=bSWbMnKe)
Dec 16, 2022
14+ million years of life come from an astonishingly modest investment
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-12/FrontLineHead.Blanke.2022-web-sized_0.png?itok=JyeLhvNL)
Dec 9, 2022
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-11/FrontLineHead.Blanke.2022-web-sized_2.png?itok=qR9X7toW)
![S1404 QoL results](/sites/default/files/styles/news_recent/public/news/2022-11/press-release-card-S1404-QoL.png?itok=8Gu3L8Jc)
Nov 23, 2022
Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens
![SWOG Results at SABCS 2022](/sites/default/files/styles/news_recent/public/news/2022-11/press-release-card-SABCS22_1.png?itok=c8DF3-LO)
Nov 21, 2022
SWOG researchers will present 10 abstracts at SABCS 2022. Here are highlights.
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-11/FrontLineHead.Blanke.2022-web-sized_1.png?itok=DOmEJ8PM)
Nov 18, 2022